PRME

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Wall Street analysts forecast PRME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRME is 6.08 USD with a low forecast of 4.25 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prime Medicine Inc revenue for the last quarter amounts to 1.23M USD, increased 486.12 % YoY.

Prime Medicine Inc. EPS for the last quarter amounts to -0.32 USD, decreased -27.27 % YoY.

Prime Medicine Inc (PRME) has 214 emplpoyees as of December 16 2025.

Today PRME has the market capitalization of 729.26M USD.